Taken together, these data demonstrate that across multiple UC cell lines, short-term priming with rosiglitazone enhances sensitivity to NECTIN4-CAR T cells, without increasing potential on-target, off-tumor toxicity to normal skin keratinocytes or normal bladder epithelial cells. The gene discussed is NECTIN4; the disease is neoplasm.